Announcements Trials

Browse Landscape

Phase

Phase 2/3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Temozolomide 11 Lomustine 6 Radiotherapy 4 Magnetic Resonance Spectroscopy 3 Etoposide 3 Carboplatin 3 Bevacizumab 3 vocimagene amiretrorepvec 2 Vincristine 2 Radiation 2 Gefitinib 2 veliparib 1 trofosfamide 1 trametinib 1 tozuleristide 1 tinostamustine 1 regorafenib 1 omburtamab I-131 1 entrectinib 1 dabrafenib 1 cobimetinib 1 carbon-11 acetate 1 capmatinib 1 antisecretory factor 1 alectinib 1 Vorinostat 1 Vemurafenib 1 Thiotepa 1 Sunitinib 1 Standard of Care 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × antisecretory factor × CNS × Clear all

NCT05669820 2026-01-09

AFGB2

Skane University Hospital

Phase 2/3 Recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡